大脑活动的生成预测增强了阿尔茨海默氏症的分类和解释
Yutong Gao1, Vince D Calhoun1, Robyn L Miller1
1Tri-Institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS).
ArXiv
|November 22, 2024
概括
这项研究使用像BrainLM这样的深度学习模型进行生成预测,以从静止状态fMRI数据中改进阿尔茨海默病 (AD) 的分类. 这种新的方法通过增加有限的数据集来提高诊断准确性.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 了解大脑活动和认知是至关重要的,但具有挑战性.
- 静态fMRI (rs-fMRI) 提供复杂的大脑数据,但深度学习模型在有限的数据集下扎,特别是对于像阿尔茨海默氏症 (AD) 这样的疾病.
研究的目的:
- 使用多变量时间序列预测探索rs-fMRI的数据增强.
- 评估深度学习模型,包括一个新的基于变压器的BrainLM,用于AD分类.
- 为了证明生成预测如何提高分类性能.
主要方法:
- 利用来自rs-fMRI的独立组件网络.
- 采用传统的基于LSTM的模型和基于变压器的新型BrainLM进行时间序列预测.
- 评估模型在对阿尔茨海默病的分类中的表现.
主要成果:
- 生成式预测显著提高了AD分类的性能.
- 基于变压器的BrainLM模型在捕捉疾病特异性模式方面表现出有希望.
- 对BrainLM的后期解释确定了与AD相关的类特定的大脑网络敏感性.
结论:
- 生成式预测是rs-fMRI研究的可行数据增强策略.
- 深度学习,特别是像BrainLM这样的变压器模型,可以改善AD检测.
- 通过网络敏感性分析,BrainLM提供了对AD的神经生物学基础的洞察.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.4K
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.8K
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827